The effectiveness of substance use interventions for homeless and vulnerably housed persons:  A systematic review of systematic reviews on supervised consumption facilities, managed alcohol programs, and pharmacological agents for opioid use disorder

Autoři: Olivia Magwood aff001;  Ginetta Salvalaggio aff002;  Michaela Beder aff003;  Claire Kendall aff001;  Victoire Kpade aff001;  Wahab Daghmach aff001;  Gilbert Habonimana aff001;  Zack Marshall aff006;  Ellen Snyder aff007;  Tim O’Shea aff008;  Robin Lennox aff009;  Helen Hsu aff010;  Peter Tugwell aff010;  Kevin Pottie aff001
Působiště autorů: C.T. Lamont Primary Health Care Research Centre, Bruyère Research Institute, Ottawa, ON, Canada aff001;  Department of Family Medicine, University of Alberta, Edmonton, AB, Canada aff002;  St. Michael’s Hospital, University of Toronto Dept of Psychiatry, Toronto, ON, Canada aff003;  Departments of Family Medicine & School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada aff004;  Department of Medicine, McGill University, Montreal, QC, Canada aff005;  School of Social Work, McGill University, Montreal, QC, Canada aff006;  Public Health and Preventative Medicine Residency Program, University of Ottawa, Ottawa, ON, Canada aff007;  Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, ON, Canada aff008;  Department of Family Medicine, McMaster University, Hamilton, ON, Canada aff009;  Department of Medicine, University of Ottawa, Ottawa, ON, Canada aff010
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227298



Substance use is disproportionately high among people who are homeless or vulnerably housed. We performed a systematic overview of reviews examining the effects of selected harm reduction and pharmacological interventions on the health and social well-being of people who use substances, with a focus on homeless populations.

Methods and findings

We searched MEDLINE, EMBASE, PsycINFO, Joanna Briggs Institute EBP, Cochrane Database of Systematic Reviews and DARE for systematic reviews from inception to August 2019. We conducted a grey literature search and hand searched reference lists. We selected reviews that synthesized evidence on supervised consumption facilities, managed alcohol programs and pharmacological interventions for opioid use disorders. We abstracted data specific to homeless or vulnerably housed populations. We assessed certainty of the evidence using the GRADE approach.

Our search identified 483 citations and 30 systematic reviews met all inclusion criteria, capturing the results from 442 primary studies. This included three reviews on supervised consumption facilities, 24 on pharmacological interventions, and three on managed alcohol programs. Supervised consumption facilities decreased lethal overdoses and other high risk behaviours without any significant harm, and improved access to care. Pharmaceutical interventions reduced mortality, morbidity, and substance use, but the impact on retention in treatment, mental illness and access to care was variable. Managed alcohol programs reduced or stabilized alcohol consumption. Few studies on managed alcohol programs reported deaths.


Substance use is a common chronic condition impacting homeless populations. Supervised consumption facilities reduce overdose and improve access to care, while pharmacological interventions may play a role in reducing harms and addressing other morbidity. High quality evidence on managed alcohol programs is limited.

Klíčová slova:

Alcohol consumption – Death rates – Drug therapy – Heroin – Housing – Morbidity – Opioids – Systematic reviews


1. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. Lancet (London, England). 2018 Jan;391(10117):241–50.

2. Bramley G, Fitzpatrick S, Edwards J, Ford D, Johnsen S, Sosenko F, et al. Hard Edges Mapping severe and multiple disadvantage England. 2015.

3. Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. Lancet. 2014;384(9953):1529–40. doi: 10.1016/S0140-6736(14)61132-6 25390578

4. Feng C, DeBeck K, Kerr T, Mathias S, Montaner J, Wood E. Homelessness independently predicts injection drug use initiation among street-involved youth in a Canadian setting. J Adolesc Health. 2012/09/25. 2013 Apr;52(4):499–501. doi: 10.1016/j.jadohealth.2012.07.011 23299006

5. Johnson TP, Fendrich M. Homelessness and drug use: evidence from a community sample. Am J Prev Med. 2007 Jun;32(6 Suppl):S211–8. doi: 10.1016/j.amepre.2007.02.015 17543713

6. McVicar D, Moschion J, van Ours JC. From substance use to homelessness or vice versa? Soc Sci Med. 2015 Jul;136–137:89–98. doi: 10.1016/j.socscimed.2015.05.005 25989002

7. Luchenski S, Maguire N, Aldridge RW, Hayward A, Story A, Perri P, et al. What works in inclusion health: overview of effective interventions for marginalised and excluded populations. Lancet. 2018;391(10117):266–80. doi: 10.1016/S0140-6736(17)31959-1 29137868

8. Khoury L, Tang YL, Bradley B, Cubells JF, Ressler KJ. Substance use, childhood traumatic experience, and Posttraumatic Stress Disorder in an urban civilian population. Depress Anxiety. 2010 Dec;27(12):1077–86. doi: 10.1002/da.20751 21049532

9. Palepu A, Gadermann A, Hubley AM, Farrell S, Gogosis E, Aubry T, et al. Substance use and access to health care and addiction treatment among homeless and vulnerably housed persons in three Canadian cities. PLoS One. 2013;8(10):e75133. doi: 10.1371/journal.pone.0075133 24124470

10. Henwood BF, Padgett DK, Tiderington E. Provider views of harm reduction versus abstinence policies within homeless services for dually diagnosed adults. J Behav Health Serv Res. 2014 Jan;41(1):80–9. doi: 10.1007/s11414-013-9318-2 23404076

11. Paquette K, Pannella Winn LA. The Role of Recovery Housing: Prioritizing Choice in Homeless Services. J Dual Diagn. 2016;12(2):153–62. doi: 10.1080/15504263.2016.1175262 27064834

12. Howie the Harp. Independent living with support services: The goal and future for mental health consumers. Psychosoc Rehabil J. 1990;13(4):85–9.

13. Milloy M-J, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. AIDS Patient Care STDS. 2012;26(1):60–7. doi: 10.1089/apc.2011.0169 22107040

14. Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Heal. 2011;88(3):545–55.

15. Coltman L, Gapka S, Harriott D, Koo M, Reid J, Zsager A. Understanding Community Integration in a Housing-First Approach: Toronto At Home/Chez Soi Community-Based Research. Intersect A Glob J Soc Work Anal Res Polity, Pract Vol 4, No 2 Intersect. 2015 Jun;

16. Hwang SW, Burns T. Health interventions for people who are homeless. Lancet (London, England). 2014 Oct;384(9953):1541–7.

17. Frankish CJ, Hwang SW, Quantz D. Homelessness and health in Canada: research lessons and priorities. Can J Public Health. 2005;96 Suppl 2:S23–9.

18. Boucher LM, Marshall Z, Martin A, Larose-Hebert K, Flynn J V, Lalonde C, et al. Expanding conceptualizations of harm reduction: results from a qualitative community-based participatory research study with people who inject drugs. Harm Reduct J. 2017 May;14(1):18. doi: 10.1186/s12954-017-0145-2 28494774

19. Buccieri K. Harm reduction as practice: Perspectives from a community of street youth and social service providers. Soc Dev Issues. 2010;32(3):1–15.

20. Klein A. Criminal law and the counter-hegemonic potential of harm reduction. Dalhous Law J. 2015;38(2):447–72.

21. Vakharia SP, Little J. Starting Where the Client Is: Harm Reduction Guidelines for Clinical Social Work Practice. Clin Soc Work J. 2017;45(1):65–76.

22. Canadian Nurses Association. Harm Reduction & Illicit Substance Use Implications for Nursing. 2017.

23. Pauly BB, Reist D, Belle-Isle L, Schactman C. Housing and harm reduction: what is the role of harm reduction in addressing homelessness? Int J Drug Policy. 2013 Jul;24(4):284–90. doi: 10.1016/j.drugpo.2013.03.008 23623720

24. British Columbia Centre on Substance Use. A Guideline for the Clinical Management of Opioid Use Disorder. 2017. p. 1–77.

25. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry. 2007 Jul;191:55–62. doi: 10.1192/bjp.bp.106.026112 17602126

26. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr;336(7650):924 LP–926.

27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 19621072

28. Shoemaker E, Kendall C, Mathew C, Crispo S, Welch V, Andermann A, et al. Establishing need and population priorities to improve the health of homeless and vulnerably housed women, youth, and men: a Delphi consensus study. submitted.

29. Magwood O, Salvalaggio G, Pottie K. Harm reduction and pharmacotherapeutic interventions for the homeless and vulnerably housed: An empty systematic review. Cochrane Equity Methods [internet] [Internet]. 2019; Available from:

30. Kpade V, Magwood O, Salvalaggio G, Daghmach W, Hannigan T, Pottie K. Harm reduction and pharmacotherapeutic interventions for persons with substance use disorders: A protocol for a systematic review of reviews. Cochrane Methods Equity. 2018.

31. Canadian Observatory on Homelessness. Canadian Definition of Homelessness. Can Obs Homelessness Press [Internet]. 2012; Available from:

32. Hwang SW, Aubry T, Palepu A, Farrell S, Nisenbaum R, Hubley AM, et al. The health and housing in transition study: A longitudinal study of the health of homeless and vulnerably housed adults in three Canadian cities. Int J Public Health [Internet]. 2011;56(6):609–23. Available from: file:///C:/Users/eshoemak/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Hwang et al. - 2011—The health and housing in transition study A longitudinal study of the health of homeless and vulnerably housed ad.pdf doi: 10.1007/s00038-011-0283-3 21858461

33. Drug Policy Alliance. Supervised Consumption Services. 2018.

34. Shepherds of Good Hope. Managed Alcohol Programs (MAP).

35. Institute of Medicine (US) Committee on Monitoring Access to Personal Health Care Services; Millman M editor. Access to Health Care in America [Internet]. Washington (DC); 1993. Available from:

36. U.S. Department of Health and Human Services O of DP and HP. Access to Health Services [Internet]. Healthy People 2020. [cited 2016 Apr 14]. Available from:

37. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016 Dec;5(1):210. doi: 10.1186/s13643-016-0384-4 27919275

38. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017 Sep;358:j4008. doi: 10.1136/bmj.j4008 28935701

39. Pollock M, Fernandes R, Becker L, Pieper D, Hartling L. Cochrane Guidance for Overviews of Reviews. Draft version. In: Higgins J, Thomas J, Chandler J, Cumpstom M, Li T. Page M, Welch V, editors. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane; 2018.

40. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. A Prod from ESRC methods Program Version. 2006;1:b92.

41. Bahji A, Bajaj N. Opioids on trial: A systematic review of interventions for the treatment and prevention of opioid overdose. Can J Addict. 2018;9(1):26–33.

42. Clark N, Lintzeris N, Gijsbers A, Whelan G, Dunlop A, Ritter A, et al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane database Syst Rev. 2002;(2):CD002210. doi: 10.1002/14651858.CD002210 12076441

43. Ferri M, Davoli M, Perucci CA. Heroin maintenance treatment for chronic heroin-dependent individuals: a Cochrane systematic review of effectiveness. J Subst Abuse Treat. 2006 Jan;30(1):63–72. doi: 10.1016/j.jsat.2005.09.003 16377453

44. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8).

45. Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012 Nov;107 Suppl:5–27.

46. Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evidence-based Med public Heal. 2016;2.

47. Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction. 2002 Oct;97(10):1241–9. doi: 10.1046/j.1360-0443.2002.00217.x 12359026

48. Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev. 2014 Mar;33(2):115–28. doi: 10.1111/dar.12095 24299657

49. Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane database Syst Rev. 2008 Apr;(2):CD006140. doi: 10.1002/14651858.CD006140.pub2 18425938

50. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database Syst Rev. 2014 Feb;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4 24500948

51. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane database Syst Rev. 2009 Jul;(3):CD002209. doi: 10.1002/14651858.CD002209.pub2 19588333

52. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane database Syst Rev. 2011 Apr;(4):CD001333. doi: 10.1002/14651858.CD001333.pub4 21491383

53. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane database Syst Rev. 2017 Sep;9:CD012021. doi: 10.1002/14651858.CD012021.pub2 28922449

54. Roozen HG, de Waart R, van der Windt DAWM, van den Brink W, de Jong CAJ, Kerkhof AJFM. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol. 2006 Jul;16(5):311–23. doi: 10.1016/j.euroneuro.2005.11.001 16361086

55. Saulle R, Vecchi S, Gowing L. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Cochrane database Syst Rev. 2017 Apr;4:CD011983. doi: 10.1002/14651858.CD011983.pub2 28447766

56. Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005 Feb;55(511):139–46. 15720937

57. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017 Apr;357:j1550. doi: 10.1136/bmj.j1550 28446428

58. Helm S, Trescot AM, Colson J, Sehgal N, Silverman S. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician. 2008;11(2):225–35. 18354714

59. Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addictiondagger. Br J Psychiatry. 2015 Jul;207(1):5–14. doi: 10.1192/bjp.bp.114.149195 26135571

60. Thomas CP, Fullerton CA, Kim M, Montejano L, Lyman DR, Dougherty RH, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014 Feb;65(2):158–70. doi: 10.1176/ 24247147

61. Weinmann S, Kunstmann W, Rheinberger P. [Methadone substitution—a scientific review in the context of out-patient therapy in Germany]. Z Arztl Fortbild Qualitatssich. 2004 Nov;98(8):673–82. 15646730

62. Wilder C, Lewis D, Winhusen T. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend. 2015 Apr;149:225–31. doi: 10.1016/j.drugalcdep.2015.02.012 25735465

63. Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Socías ME, Fairbairn N, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9(4):e025799. doi: 10.1136/bmjopen-2018-025799 30944135

64. Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, et al. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. J Subst Abuse Treat. 2018;89:28–51. doi: 10.1016/j.jsat.2018.03.001 29706172

65. Kennedy MC, Karamouzian M, Kerr T. Public health and public order outcomes associated with supervised drug consumption facilities: a systematic review. Curr HIV/AIDS Rep. 2017;14(5):161–83. doi: 10.1007/s11904-017-0363-y 28875422

66. Potier C, Laprevote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: what has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014 Dec;145:48–68. doi: 10.1016/j.drugalcdep.2014.10.012 25456324

67. McNeil R, Small W. “Safer environment interventions”: A qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014;106:151–8. doi: 10.1016/j.socscimed.2014.01.051 24561777

68. Muckle W, Muckle J, Welch V, Tugwell P. Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse. Cochrane database Syst Rev. 2012 Dec;12:CD006747. doi: 10.1002/14651858.CD006747.pub2 23235633

69. Ezard N., Dolan K., Baldry E., Burns L., Day C., Hodge S., Cubitt T., Loesch B., & Mackay TT. Feasibility of a Managed Alcohol Program (MAP) for Sydney ‘ s homeless. 2015.

70. Nielsen E, Novotna G, Berenyi R, Olson N. Harm reduction interventions for chronic and severe alcohol use among populations experiencing homelessness: A literature review. Regina; 2018.

71. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009 Aug;361(8):777–86. doi: 10.1056/NEJMoa0810635 19692689

72. Pettes T, Wood E, Guillemi S, Lai C, Montaner J, Kerr T. Methadone use among HIV-positive injection drug users in a Canadian setting. J Subst Abuse Treat. 2010 Sep;39(2):174–9. doi: 10.1016/j.jsat.2010.05.001 20598827

73. Kaplan JL, Marx JA, Calabro JJ, Gin-Shaw SL, Spiller JD, Spivey WL, et al. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med. 1999 Jul;34(1):42–50. doi: 10.1016/s0196-0644(99)70270-2 10381993

74. Kelly A-M, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005 Jan;182(1):24–7. 15651944

75. Kerr D, Kelly A-M, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009 Dec;104(12):2067–74. doi: 10.1111/j.1360-0443.2009.02724.x 19922572

76. Rupreht J, Dworacek B, Oosthoek H, Dzoljic MR, Valkenburg M. Physostigmine versus naloxone in heroin-overdose. J Toxicol Clin Toxicol. 1983;21(3):387–97. doi: 10.3109/15563658308990429 6676478

77. Government of Canada. Vancouver’s INSITE Service and Other Supervised Injection Sites: What Has Been Learned from Research?—Final Report of the Expert Advisory Committee on Supervised Injection Site Research. 2008.

78. Committee ME. Final report of the evaluation of the Sydney Medically Supervised Injecting Centre. MSIC Evaluation Committee; 2003.

79. Jackson LA, McWilliam S, Martin F, Dingwell J, Dykeman M, Gahagan J, et al. Key challenges in providing services to people who use drugs: The perspectives of people working in emergency departments and shelters in Atlantic Canada. Drugs Educ Prev policy. 2014;21(3):244–53.

80. Homeless Hub. Substance Use and Addiction.

81. Khandor E, Mason K, Chambers C, Rossiter K, Cowan L, Hwang SW. Access to primary health care among homeless adults in Toronto, Canada: results from the Street Health survey. Open Med. 2011;5(2):e94–103. 21915240

82. Mericle AA, Grella CE. Integrating Housing and Recovery Support Services: Introduction to the Special Section. Vol. 12, Journal of dual diagnosis. United States; 2016. p. 150–2. doi: 10.1080/15504263.2016.1176408 27070498

83. Meges D, Zevin B, Cookson E, Bascelli L, Denning P, Little J, et al. Adapting your practice: Recommendations for the care of homeless patients with opioid use disorders. Nashville, TN Natl Heal Care Homeless Counc Inc. 2014;

84. Canavan R, Barry MM, Matanov A, Barros H, Gabor E, Greacen T, et al. Service provision and barriers to care for homeless people with mental health problems across 14 European capital cities. BMC Health Serv Res. 2012;12(1):222.

85. Krausz RM, Clarkson AF, Strehlau V, Torchalla I, Li K, Schuetz CG. Mental disorder, service use, and barriers to care among 500 homeless people in 3 different urban settings. Soc Psychiatry Psychiatr Epidemiol. 2013;48(8):1235–43. doi: 10.1007/s00127-012-0649-8 23299926

86. Campbell DJT, O’Neill BG, Gibson K, Thurston WE. Primary healthcare needs and barriers to care among Calgary’s homeless populations. BMC Fam Pract. 2015;16(1):139.

87. Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–56. doi: 10.1503/cmaj.190344 31548191

88. van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013 Jul;131(1–2):23–35. doi: 10.1016/j.drugalcdep.2013.02.018 23490450

89. Srivastava A, Kahan M, Nader M. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017 Mar;63(3):200–5. 28292795

90. Perry D, Orrantia E, Garrison S. Treating opioid use disorder in primary care. Can Fam Physician. 2019 Feb;65(2):117. 30765361

91. Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv drug Saf. 2018 Jan;9(1):63–88. doi: 10.1177/2042098617744161 29318006

92. Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. 2015 Jul;14(7):1137–46. doi: 10.1517/14740338.2015.1037274 25865597

93. McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016 Jul;111(7):1177–87. doi: 10.1111/add.13326 27028542

94. Chimbar L, Moleta Y. Naloxone Effectiveness: A Systematic Review. J Addict Nurs. 2018;29(3):167–71. doi: 10.1097/JAN.0000000000000230 30180002

95. Baggett TP, Hwang SW, O’Connell JJ, Porneala BC, Stringfellow EJ, Orav EJ, et al. Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med. 2013 Feb;173(3):189–95. doi: 10.1001/jamainternmed.2013.1604 23318302

96. Bauer LK, Brody JK, Leon C, Baggett TP. Characteristics of Homeless Adults Who Died of Drug Overdose: A Retrospective Record Review. J Health Care Poor Underserved. 2016;27(2):846–59. doi: 10.1353/hpu.2016.0075 27180712

97. Pietrusza LM, Puskar KR, Ren D, Mitchell AM. Evaluation of an Opiate Overdose Educational Intervention and Naloxone Prescribing Program in Homeless Adults Who Use Opiates. J Addict Nurs. 2018;29(3):188–95. doi: 10.1097/JAN.0000000000000235 30180005

98. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice. Subst Abus. 2015;36(2):240–53. doi: 10.1080/08897077.2015.1010032 25774771

99. Dong K, Taylor M, Wild C, Villa-Roel C, Rose M, Salvalaggio G, et al. Community-based naloxone: a Canadian pilot program. Can J Addict. 2012;3(2):4–9.

100. McKnight I, Maas B, Wood E, Tyndall MW, Small W, Lai C, et al. Factors associated with public injecting among users of Vancouver’s supervised injection facility. Am J Drug Alcohol Abuse. 2007;33(2):319–25. doi: 10.1080/00952990601175102 17497555

101. Milloy M, Wood E. Emerging Role Of Supervised Injecting Facilities In Human Immunodeficiency Virus Prevention. Addiction. 2009;104(4):620–1. doi: 10.1111/j.1360-0443.2009.02541.x 19335659

102. Bayoumi AM, Strike CJ. Making the case for supervised injection services. Lancet (London, England). 2016 May;387(10031):1890–1.

103. Strike C, Jairam JA, Kolla G, Millson P, Shepherd S, Fischer B, et al. Increasing public support for supervised injection facilities in Ontario, Canada. Addiction. 2014 Jun;109(6):946–53. doi: 10.1111/add.12506 24520984

104. Strike C, Watson TM, Kolla G, Penn R, Bayoumi AM. Ambivalence about supervised injection facilities among community stakeholders. Harm Reduct J. 2015 Aug;12:26. doi: 10.1186/s12954-015-0060-3 26292715

105. Strike C, Rotondi NK, Watson TM, Kolla G, Bayoumi AM. Public opinions about supervised smoking facilities for crack cocaine and other stimulants. Subst Abuse Treat Prev Policy. 2016 Feb;11:8. doi: 10.1186/s13011-016-0052-7 26860540

106. Bardwell G, Scheim A, Mitra S, Kerr T. Assessing support for supervised injection services among community stakeholders in London, Canada. Int J Drug Policy. 2017 Oct;48:27–33. doi: 10.1016/j.drugpo.2017.05.009 28666204

107. Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017;14(1):28. doi: 10.1186/s12954-017-0154-1 28521829

108. Mema SC, Frosst G, Bridgeman J, Drake H, Dolman C, Lappalainen L, et al. Mobile supervised consumption services in Rural British Columbia: lessons learned. Harm Reduct J. 2019 Jan;16(1):4. doi: 10.1186/s12954-018-0273-3 30634986

109. University of Victoria. The Canadian Managed Alcohol Program Study (CMAPS).

110. Evans J, Semogas D, Smalley JG, Lohfeld L. “This place has given me a reason to care”: Understanding “managed alcohol programs” as enabling places in Canada. Health Place. 2015 May;33:118–24. doi: 10.1016/j.healthplace.2015.02.011 25817940

111. Pauly BB, Gray E, Perkin K, Chow C, Vallance K, Krysowaty B, et al. Finding safety: a pilot study of managed alcohol program participants’ perceptions of housing and quality of life. Harm Reduct J. 2016 May;13(1):15. doi: 10.1186/s12954-016-0102-5 27156564

112. Pauly BB, Vallance K, Wettlaufer A, Chow C, Brown R, Evans J, et al. Community managed alcohol programs in Canada: Overview of key dimensions and implementation. Drug Alcohol Rev. 2018 Apr;37 Suppl 1:S132–9.

113. Moberg J, Oxman AD, Rosenbaum S, Schünemann HJ, Guyatt G, Flottorp S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Heal Res policy Syst. 2018;16(1):45.

114. Rush B, Urbanoski K. Seven Core Principles of Substance Use Treatment System Design to Aid in Identifying Strengths, Gaps, and Required Enhancements. J Stud Alcohol Drugs Suppl. 2019 Jan;Sup 18:9–21.

115. Tremblay J, Bertrand K, Blanchette-Martin N, Rush B, Savard A-C, L’Esperance N, et al. Estimation of Needs for Addiction Services: A Youth Model. J Stud Alcohol Drugs Suppl. 2019 Jan;Sup 18:64–75.

116. Andresen MA, Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver’s supervised injection facility. Int J Drug Policy. 2010 Jan;21(1):70–6. doi: 10.1016/j.drugpo.2009.03.004 19423324

117. Jozaghi E, Reid AA, Andresen MA. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada. Subst Abuse Treat Prev Policy. 2013 Jul;8:25. doi: 10.1186/1747-597X-8-25 23837814

118. Milby JB, Schumacher JE, Vuchinich RE, Freedman MJ, Kertesz S, Wallace D. Toward cost-effective initial care for substance-abusing homeless. J Subst Abuse Treat. 2008 Mar;34(2):180–91. doi: 10.1016/j.jsat.2007.03.003 17512156

119. Marshall Z, Dechman MK, Minichiello A, Alcock L, Harris GE. Peering into the literature: A systematic review of the roles of people who inject drugs in harm reduction initiatives. Drug Alcohol Depend. 2015 Jun;151:1–14. doi: 10.1016/j.drugalcdep.2015.03.002 25891234

120. Hughes CE, Stevens A. The effects of the decriminalization of drug use in Portugal. 2007.

121. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Vol. 20, The International journal on drug policy. Netherlands; 2009. p. 193–201. doi: 10.1016/j.drugpo.2008.10.003 19147339

122. Patterson ML, Rezansoff S, Currie L, Somers JM. Trajectories of recovery among homeless adults with mental illness who participated in a randomised controlled trial of Housing First: a longitudinal, narrative analysis. BMJ Open. 2013 Sep;3(9):e003442. doi: 10.1136/bmjopen-2013-003442 24022392

123. Shannon K, Rusch M, Shoveller J, Alexson D, Gibson K, Tyndall MW. Mapping violence and policing as an environmental-structural barrier to health service and syringe availability among substance-using women in street-level sex work. Int J Drug Policy. 2008 Apr;19(2):140–7. doi: 10.1016/j.drugpo.2007.11.024 18207725

124. Martins DC. Experiences of homeless people in the health care delivery system: a descriptive phenomenological study. Public Health Nurs. 2008;25(5):420–30. doi: 10.1111/j.1525-1446.2008.00726.x 18816359

125. Truong M, Paradies Y, Priest N. Interventions to improve cultural competency in healthcare: a systematic review of reviews. BMC Health Serv Res. 2014 Mar;14:99. doi: 10.1186/1472-6963-14-99 24589335

Článek vyšel v časopise


2020 Číslo 1